National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Naloxegel (Moventiq®) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

Rapid Review

Commenced Completed Outcome
10/02/2015 13/04/2015 Full Pharmacoeconomic Evaluation Not Recommended

Naloxegel (Moventiq®) is to be reimbursed under the Community Drugs Schemes subject to conditions.